Banxia Xiexin Decoction () Treats Diabetic Gastroparesis through PLC-IP
10.1007/s11655-020-3077-8
- Author:
Bin WANG
1
;
Ke-Wu ZENG
2
;
Zi-Fu HONG
3
;
Gui-Xiang TI
4
;
Li-Yun WANG
4
;
Pin LU
4
;
Zhen LIU
5
Author Information
1. Department of Andrology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
2. Department of Natural Medicines, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
3. Department of Anorectal, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
4. Department of Prevention and Health Care, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
5. Department of Gastroenterology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China. gampku@163.com.
- Publication Type:Journal Article
- Keywords:
Banxia Xiexin Decoction;
Chinese medicine;
diabetic gastroparesis;
phospholipase C-inositol triphosphate-calcium/nitric oxide-cyclic guanosine monophosphate-cyclic guanosine monophosphate dependent protein kinase G
- From:
Chinese journal of integrative medicine
2020;26(11):833-838
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To test the effect of Banxia Xiexin Decoction (, BXD) on the contraction and relaxation of gastric smooth muscle (SM) in diabetic gastroparesis (DGP) model rats, and to explore the mechanism of BXD in the prevention and treatment of DGP through experiments of signal pathway both in vivo and in vitro.
METHODS:Sixty Sprague-Dawley rats were divided into 6 groups according to a random number table: control group, model group, high-, medium- and low-dose BXD groups (9.2, 4.6 and 1.8 g/(kg·d), respectively), and domperidone group (10 mg/(kg·d)), 10 rats per group. DGP model was established initially by a single intraperitoneal injection of streptozotocin (STZ), and was confirmed by recording gastric emptying, intestinal transport velocity and gastric myoelectric activity of rats after 2 months. Each group was treated with a corresponding drug for 4 weeks. The mRNA and protein expressions of phospholipase C (PLC), inositol triphosphate (IP
RESULTS:Compared with the model group, high- and medium-dose BXD and domperidone significantly increased the expressions of PLC, IP
CONCLUSIONS:Treatment with high- and medium-dose BXD significantly attenuated STZ-induced experimental DGP in rats. The therapeutic effect of BXD on DGP rats might be associated with the PLC-IP
